{"filing":{"accession_number":"0001213900-26-098123","cik":"0001844417","ticker":"ESLAW","company_name":"Estrella Immunopharma, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-01","primary_document":"ea030490301-8k_estrella.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1844417/000121390026098123/ea030490301-8k_estrella.htm"},"events":[{"id":32091,"run_id":29480,"accession_number":"0001213900-26-098123","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Estrella Immunopharma received written notification from Nasdaq on September 1, 2026, that it failed to meet the minimum market value of listed securities (MVLS) requirement of $35,000,000 for 30 consecutive business days. The company has been granted a 180-day compliance period until March 1, 2027, to regain compliance, with the explicit warning that failure to do so will result in delisting notification. This is a classic delisting-risk disclosure under Item 3.01.","company_name":"Estrella Immunopharma, Inc.","ticker":"ESLAW","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35175,"accession_number":"0001213900-26-098123","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Estrella Immunopharma received written notification from Nasdaq on September 1, 2026, that it failed to meet the minimum market value of listed securities (MVLS) requirement of $35,000,000 for 30 consecutive business days. The company has been granted a 180-day compliance period until March 1, 2027, to regain compliance, with the explicit warning that failure to do so will result in delisting notification. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:27:36.982306+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35175,"accession_number":"0001213900-26-098123","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Estrella Immunopharma received written notification from Nasdaq on September 1, 2026, that it failed to meet the minimum market value of listed securities (MVLS) requirement of $35,000,000 for 30 consecutive business days. The company has been granted a 180-day compliance period until March 1, 2027, to regain compliance, with the explicit warning that failure to do so will result in delisting notification. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:27:36.982306+00:00","company_name":"Estrella Immunopharma, Inc.","ticker":"ESLAW","filing_date":"2026-09-08"}]}